Amgen (AMGN) Valuation Check After FDA Expansion of UPLIZNA in Generalized Myasthenia Gravis

Amgen (AMGN) just picked up a meaningful FDA win, with UPLIZNA cleared for a specific subset of adults with generalized ...

Amphenol: Structural Growth Reaccelerates, Rating Upgraded To Buy

Amphenol is upgraded to Buy with a $148 target, reflecting a 13% upside after a record Q3 and raised forecasts. Learn more ...